Glycyrrhetinic Acid Functionalized Nanoparticles for Drug Delivery to Liver Cancer
August 2018
in “
Journal of biomedical nanotechnology
”
Studysummary This review highlights GA-mediated nanoparticles for liver-targeting drug delivery in liver cancer treatment and reports no new clinical results.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The document reviewed the use of glycyrrhetinic acid (GA) functionalized nanoparticles for liver-targeting drug delivery systems in liver cancer treatment. Liver cancer is a prevalent malignancy, and while chemotherapy is a primary treatment, it often leads to severe side effects like leukopenia, digestive issues, hepatic and renal dysfunction, and hair loss. GA, derived from licorice root, binds specifically to hepatocytes, making it a promising agent for targeted drug delivery. The review focused on the development and potential of GA-mediated nanoparticles using various polymer materials to enhance liver cancer therapy.
